Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla Ltd: Solid 4QFY02 - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Apr 30, 2002

    Cipla Ltd: Solid 4QFY02

    4QFY02 would probably be a record quarter for Cipla. The company recorded a stupendeous performance far surpassing market expectations. While sales have leapfroged more than 32%, PAT recorded 80% rise, on the back of strong rise in operating margins. Operating margins have zoomed by more than 980 basis points, after recording a disappointing drop for four consequent quarters.

    (Rs m) 4QFY01 4QFY02 Change FY01 FY02 Change
    Sales 2,606 3,449 32.4% 10,477 12,776 22.0%
    Other Income 139 107 -22.5% 396 441 11.2%
    Expenditure 2,257 2,648 17.3% 8,319 9,965 19.8%
    Operating Profit (EBDIT) 348 801 130.0% 2,157 2,811 30.3%
    Operating Profit Margin (%) 13.4% 23.2%   20.6% 22.0%  
    Interest 1 5 455.6% 9 20 119.8%
    Depreciation 33 72 120.0% 155 215 38.7%
    Profit before Tax 454 832 83.4% 2,389 3,017 26.3%
    Other Adjustments -   -  
    Tax 110 215 95.5% 605 725 19.8%
    Profit after Tax/(Loss) 344 617 79.6% 1,784 2,292 28.5%
    Net profit margin (%) 13.2% 17.9%   17.0% 17.9%  
    No. of Shares (eoy) (m) 60.0 60.0   60.0 60.0  
    Diluted Earnings per share 22.9 41.1   29.7 38.2  
    P/E (at current price) 24   26

    Riding high on bulk exports mainly to developed markets, exports have registered a triple digit sales growth, contributing around 48% of total sales. Surprsingly, even the domestic sales growth has recorded a 23% growth outsmarting the industry growth rate of around 11%. Overall, a sharp change in the revenue mix resulted in a smart rise in operating margins on the back of sharp drop in cost of raw material consumed.

    Exports of CFC-free inhaler is expected to kick-start by Aug/ September' 02. Further, Cipla has tied up with several US generic companies for supply of bulk drugs, which have first to file status. Some of these products are Omeprazole, Flutamide and Olanzipine which are leading molecules in their respective therapeutic segments. Further, the company is exploring options for possible tie-ups for venturing into biotech and genetic engineering with a suitable foreign partner.

    At the current market price of Rs 990, the stock is trading at 26x its FY02 earnings. The stock is likely to see some upward movement on the back of roboust performance in the last quarter and strong triggers for the stock going forward.



    Equitymaster requests your view! Post a comment on "Cipla Ltd: Solid 4QFY02". Click here!


    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)



    Detailed Financial Information With Charts